INTRODUCTION: Cytokines have been suggested to both modulate anti-tumor responses and promote tumor growth. MATERIALS AND METHODS: We analyzed the expression of pro-inflammatory IL-12p35, IL-12p40, IL-23p19, anti-inflammatory IL-10, antiapoptotic factor survivin, and transcription factors-RelA, c-Jun, and Foxp3 mRNA in patients' blood, colon carcinoma tissue, and in normal mucosal tissue by real-time polymerase chain reaction. The quantity determination of serum IL-12p40, IL-23, and IL-10 was performed by enzyme-linked immunosorbent assay. RESULTS: We observed significantly higher levels in patients for all three analyzed cytokines, with IL-23 concentration change being the highest. We detected the greatest upregulation of IL-23p19, Foxp3 and survivin mRNA in colorectal carcinomas than normal mucosa. A statistically significant upregulation of IL-12p40, IL-10, and c-Jun mRNA but not for IL-12p35 and RelA mRNA in tumor tissue comparing to normal tissue was also established. CONCLUSIONS: In conclusion, we show a characteristic gene expression profile combining markers associated with inhibition of anti-tumor immune response (Foxp3, IL-10), inhibition of apoptosis (survivin), and induction of the cytokines with protumoral activity as IL-12p40 and IL-23p19 (IL-23) in the colorectal tumor tissue but not in peripheral blood of patients.
INTRODUCTION: Cytokines have been suggested to both modulate anti-tumor responses and promote tumor growth. MATERIALS AND METHODS: We analyzed the expression of pro-inflammatory IL-12p35, IL-12p40, IL-23p19, anti-inflammatory IL-10, antiapoptotic factor survivin, and transcription factors-RelA, c-Jun, and Foxp3 mRNA in patients' blood, colon carcinoma tissue, and in normal mucosal tissue by real-time polymerase chain reaction. The quantity determination of serum IL-12p40, IL-23, and IL-10 was performed by enzyme-linked immunosorbent assay. RESULTS: We observed significantly higher levels in patients for all three analyzed cytokines, with IL-23 concentration change being the highest. We detected the greatest upregulation of IL-23p19, Foxp3 and survivin mRNA in colorectal carcinomas than normal mucosa. A statistically significant upregulation of IL-12p40, IL-10, and c-Jun mRNA but not for IL-12p35 and RelA mRNA in tumor tissue comparing to normal tissue was also established. CONCLUSIONS: In conclusion, we show a characteristic gene expression profile combining markers associated with inhibition of anti-tumor immune response (Foxp3, IL-10), inhibition of apoptosis (survivin), and induction of the cytokines with protumoral activity as IL-12p40 and IL-23p19 (IL-23) in the colorectal tumor tissue but not in peripheral blood of patients.
Authors: Peter K Baier; Guido Wolff-Vorbeck; Stephan Eggstein; Ulrich Baumgartner; Ulrich T Hopt Journal: Anticancer Res Date: 2005 May-Jun Impact factor: 2.480
Authors: Graziella Bellone; Carlo Smirne; Francesco Angelo Mauri; Elena Tonel; Anna Carbone; Alessandra Buffolino; Luca Dughera; Antonio Robecchi; Mario Pirisi; Giorgio Emanuelli Journal: Cancer Immunol Immunother Date: 2005-08-11 Impact factor: 6.968
Authors: Noyko S Stanilov; Lyuba D Miteva; Zlatka G Dobreva; Jovcho P Jovchev; Geo M Cirovski; Spaska A Stanilova Journal: Mol Biol Rep Date: 2012-10-10 Impact factor: 2.316
Authors: Feng Lan; Le Zhang; Junchao Wu; Jie Zhang; Sen Zhang; Kai Li; Yanyu Qi; Ping Lin Journal: Int J Colorectal Dis Date: 2011-05-06 Impact factor: 2.571
Authors: G Bobe; G Murphy; P S Albert; L B Sansbury; E Lanza; A Schatzkin; N H Colburn; A J Cross Journal: Br J Cancer Date: 2010-10-05 Impact factor: 7.640
Authors: Cornelia Richter; Martina Herrero San Juan; Benno Weigmann; Dominik Bergis; Katrin Dauber; Michael H Muders; Gustavo B Baretton; Josef Martin Pfeilschifter; Halvard Bonig; Sebastian Brenner; Heinfried H Radeke Journal: Front Immunol Date: 2017-01-27 Impact factor: 7.561
Authors: Melina Helbling; Anne Lukesch; Aladin Haimovici; Eva Karamitopoulou; Martin D Berger; Marion Hädrich; Makhmud Mallaev; Beat Schnüriger; Viktor H Koelzer; Heather Dawson; Markus Borner; Rupert Langer; Robert Rosenberg; Ulrich Nitsche; Daniel Inderbitzin; Alessandro Lugli; Mario Tschan; Inti Zlobec Journal: Oncotarget Date: 2014-07-15